Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

55.85
+0.90001.64%
Volume:128.14K
Turnover:7.17M
Market Cap:8.04B
PE:-11.54
High:56.69
Open:55.67
Low:55.00
Close:54.95
52wk High:86.45
52wk Low:27.66
Shares:144.00M
Float Shares:116.97M
Volume Ratio:0.41
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8401
EPS(LYR):-3.8028
ROE:-20.83%
ROA:-15.07%
PB:2.78
PE(LYR):-14.69

Loading ...

Vaxcyte doses first participants in OPUS-3 trial

TIPRANKS
·
Feb 12

Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Previously Vaccinated Adults

Reuters
·
Feb 12

Vaxcyte Doses First Participants in Opus-3 Phase 3 Trial Evaluating Vax-31 in Adults Previously Vaccinated With Lower-Valency Pneumococcal Vaccines

THOMSON REUTERS
·
Feb 12

Vaxcyte Inc: Topline Data Expected in Q4 of 2026

THOMSON REUTERS
·
Feb 12

Vaxcyte Inc. to report financial results and provide business update

Reuters
·
Feb 11

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

GlobeNewswire
·
Feb 06

Vaxcyte Closes Public Offering of Shares

MT Newswires Live
·
Feb 03

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
Feb 03

Vaxcyte Price Target Maintained With a $116.00/Share by Guggenheim

Dow Jones
·
Feb 02

Vaxcyte (PCVX) Valuation Check After $550 Million Follow On Equity Offering

Simply Wall St.
·
Feb 02

BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology

Reuters
·
Jan 30

BUZZ-Vaxcyte edges higher after upsized $550 mln equity raise

Reuters
·
Jan 30

Vaxcyte Inc - Selling 11,000,000 Shares at $50 per Share

THOMSON REUTERS
·
Jan 30

Vaxcyte Announces Pricing of $550 Million Public Offering

THOMSON REUTERS
·
Jan 30

Vaxcyte secondary being re-offered at $50 per share

TIPRANKS
·
Jan 30

Vaxcyte offering marketed at $50 per share, Bloomberg says

TIPRANKS
·
Jan 30

Vaxcyte Launches $500 Million Public Offering

MT Newswires Live
·
Jan 30

Vaxcyte Inc - Commences $500 Mln Public Offering

THOMSON REUTERS
·
Jan 30

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Jan 30

Why Vaxcyte (PCVX) Is Up 13.2% After Advancing Adult Phase 3 And Infant VAX-31 Trials

Simply Wall St.
·
Jan 26